Nanobiotechnology: Market Research Report

February 2010 | 827 pages | ID: NB1C79D6B6EEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following technology segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual forecasts are provided for each region for the period of 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 140 companies including many key and niche players worldwide such as Aduro BioTech, Abraxis Bioscience, Inc., Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Unidym, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Elan Pharmaceuticals, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, BioTrove, Inc., Invitrogen Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, and Zyvex Instruments LLC.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope Of Study

1. NANOMATERIALS

Solid Inorganic Nanoparticles
Nanocomposites
Nanostructured Materials and Membranes
Nanotubes and Fullerenes
Other Nanomaterials
Nanoshells
Nanohorns
Nanocapsules

2. NANODEVICES/TOOLS

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

A Curtain Raiser
Nanobiotechnology – The Next Big Thing
Nanotechnology & Biology Tie the Knot: “Two to Tango”
Where Conventional Molecular Science Falls Short Nanobio Steps In
What’s The Obsession With Size?
Why Analysis at the Cellular Level is Important?
Lessons from Nature
Dawn Breaks On Nanobiotechnology

Table 1. Nanobiotechnology and Related Medical Applications Market (2007): Percentage Share Breakdown of Activity Distribution by Region and Organizational Set-Up (includes corresponding Graph/Chart)

Table 2. Percentage Breakdown of Number of Nanotechnology Companies in Healthcare Industry Worldwide by Region/ Country (2008) (includes corresponding Graph/Chart)

Table 3. Percentage Breakdown of Number of Nanotechnology Companies in Healthcare Industry Worldwide by Type – Private and Public Sector (2008)

Table 4. Percentage Breakdown of Number of Nanotechnology Companies in Healthcare Industry Worldwide By Sector – Therapeutics and Drug Delivery; Clinical Diagnostics; Drug Discovery Tools and Biomedical Research; and Biomaterials and Biomedical Implants (2008) (includes corresponding Graph/Chart)

Table 5. Percentage Breakdown of Number of Nanotechnology Companies in The field of Therapeutics and Drug Delivery Worldwide by Area - Targeted Nanoparticles, Solubility & Reformulation, Sustained Release, Blood Brain Barrier, Nanomaterial Therapeutics and Others (2008) (includes corresponding Graph/Chart)

Table 6. Percentage Breakdown of Number of Nanotechnology Companies in the field Therapeutics Worldwide by Therapeutic Area – Oncology, Infectious Diseases, Central Nervous System Diseases, Nutraceuticals, Ophthalmology and Others (2008) (includes corresponding Graph/Chart)

Table 7. Percentage Breakdown of Number of Nanotechnology Companies in the field of Clinical Imaging and Diagnostics Worldwide by Area – Tags and Probes; Imaging Agents; Biosensors and Bio-detection; and Instruments (2008) (includes corresponding Graph/Chart)

Demystifying the Intriguing World of Nanobiotech
A Meeting Place of Medicine’s Best Solutions
Nanobiotechnology Promises to Deliver Nanomedicine
Nanobiotechnology to Become Viable for All Drug Development Stages
Nanobioproducts in R&D As of 2007 & 2008
List of Marketed Nanoparticle-Based Pharmaceutical Products As of the Year 2007
Nanoparticles: The Foundation of Nanobiotechnology
Improved Optical Properties and Stability of Nanoparticles
Nanoemulsions
Diagnosis & Treatment of Cancer
Challenges
Commercial Exploration: A Treacherous Voyage
Conventional Medicine to Contest Nanomedicine Adoption
Nanomaterials Use: Weighed Down with Toxicity Concerns
Production Issues Continue to Plague Nanobiotech Industry
Lack of De Facto Standards: A Challenge to Reckon With
The Promise of Nanobiotechnology
Biological Weaponries Against Diseases Come in Small Packages
Proffered Benefits of Nanobiotechnology
Opportunity & Beyond
Nanobiotechnology – Will it Live Up to the Expectations?
The Future of Nanobiotechnology: Shape of Things to Come
Nanobiotechnology: The Outer Limits
Futuristics: A Rumination
Nanobiotechnology In the Year 2015
Field of Nanodiagnostics
Field of Regenerative Medicine
Field of Targeted Drug Delivery
Conclusions

2.MARKET DYNAMICS

Nanotechnology in the Current Economic Climate: A Review
Nanobio Feels the Pinch or Does It…?: A Closer Look

Table 8. Global Nanobiotechnology Market (2007): Percentage Share Breakdown of Investments by Region (includes corresponding Graph/Chart)

Government Funding of Nanotechnology Slows Down

Table 9. Worldwide Government Funding in Nanotechnology (2008-2015) (In US$ Billion) (includes corresponding Graph/Chart)

Developing Countries to Rise Over the Horizon

Table 10. Worldwide Funding in Nanotechnology (2004 & 2009): Percentage Breakdown of Value Investments by Country/Region: A Comparison (includes corresponding Graph/Chart)

Consolidation Sharpens the Industry’s Edge
Demand for Novel Products to Push Up Growth
The Regulatory Framework Evolves with the Technology
Nanomaterials & Nanoparticles Witness Robust Activity
Quantum Dot Patents Pose Legal Tangles
Miniaturized Liquid Handling Becomes Progressive
Trends in Nanotechnology Enabled Drug Delivery Systems
Robust Growth On Cards

Table 11. Global Nanotechnology-Enabled Drug Delivery Systems Market (2015 (P)): Percentage Share Breakdown of Nanoparticles, Dendrimers, Polymer Therapeutics and Other Nanostructures (includes corresponding Graph/Chart)

Patent Expiries: A Key Driver
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs

3.INDUSTRY ISSUES

Embroilment Over Ethical Issues
Social Relevance
Economic Relevance

4.INDUSTRY STRUCTURE

Industry Structure: A Quick Primer
A Dissection of Select Segments
Nanoparticles
Nanotubes and Fullerenes
Dendrimers
A Peek Into the Regulatory Framework
United States
Europe
A Closer Look at Regional Nano Efforts
United States: Unraveling the Country’s Edge

Table 12. Global Intellectual Property Rights in Nanotechnology By Leading Countries (2007)

Europe: Hot On the Heels of the US
Germany
France
United Kingdom
Scandinavia
Japan: A Noteworthy Region

5.NANOBIO’S EPOCHAL STRIDES IN MODERN MEDICINE

A Primer
Impact on Drug Delivery Systems
Benefits Offered
Drug Encapsulation
High Level of Specificity
Increase in Drug Solubility and Uptake
Greater Usage Flexibility
Impact On Molecular Diagnostic Imaging
Seeing The Unseen
Impact On Pharmaceutical Drug Formulations
Impact On Therapeutics
Silver Nanoparticles as Effective Antimicrobial Agents
Modern Day Nanomedicine: A Current Scenario
Nanomedicine: The Cynosure of All Eyes
Drug Delivery Systems Epitomized by Nanomedicine
Targeted NanoDrug Delivery & Release
Active and Passive Targeting Mechanisms in Drug Delivery
Sustained and Pulsatile Release Mechanisms in Drug Delivery
A Peek Into Potential Nanobio Enabled Drug Carriers
Micelles:
Liposomes:
Dendrimers & Liquid Crystals:
Nanoparticles:
Polymeric Nanoparticles:
Hydrogels:
Molecularly Imprinted Polymers:
Microelectromechanical Systems (MEMS):
Nanosuspensions:
Fullerenes: A Platform for GenX Drug Delivery
Types of Nano-Based Drug Delivery Systems, Related Materials, and Structures
Dynamics of Regenerative Medicine
Tissue Engineering and Restorations
Nanotechnology Enabled Diagnostics
Promised Path Breaking Applications in Molecular Diagnostics & Imaging
In-Vitro Diagnostics
In-Vivo Diagnostics
Nanoprobes & Implantable Devices in In-vivo Imaging
Nanocomposites in Molecular Labeling & Diagnostics
Laboratory-on-a-Chip – A Revolutionary Technology in Biomolecular Detection
Biosensors – Heralding New Opportunities in Molecular Diagnostics
Nanobiosensors – A New Approach to Diagnostics Testing
Despite Huge Potential … Key Hurdles Remain in Commercialization
Magnetic Nanoparticles for Imaging Applications in MRI
Dendrimers Promise Milestone Applications in MRI
Conclusions
Gauging the Real World Impact of Nanobiotech on Cancer: A Case Study
Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents
Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes
Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis

6.TECHNOLOGY OVERVIEW

Nanotechnology: An Introduction
A Revolution in the Making
Nanobiotechnology: An Exposition
Nanobiotechnology & Medicine
Nanobiotechnology & Biofuels
Global Nanobiotechnology Market (2005): Major Products
Global Nanobiotechnology Market (2005): Major Products Under Development
Analysis of Major Technology Segments
Nanomaterials
Nanoparticles
Nanoparticles in Labeling or Bio Tagging
Nanoparticles as Biomarkers
Classification of Nanoparticles
Solid Nanoparticles
Solid Lipid Nanoparticles
Calcium Phosphate Nanoparticles
Dendrimers
Dendrimers as Templates for Synthesis of Hybrid Nanostructures
Nanocomposites
Lamellar Nanocomposites
Nanostructured Materials and Membranes
Nanotubes and Fullerenes
Other Nanomaterials
Nanoshells
Nanohorns
Nanocapsules
Nanodevices
Nanotools
Select Nanotools
Atomic Force Microscopes
Hot Embossing Lithography
Dip-Pen Nanolithography

7.GLOBAL RESEARCH CENTERS AND INSTITUTIONS

Centre for Biologic Nanotechnology (USA)
Centre for Biological and Environmental Nanotechnology (USA)
Institute of Bioengineering and Nanotechnology (Singapore)
The Nanobiotechnology Center (USA)
The Tyndall National Institute (Ireland)

8.RECENT INDUSTRY ACTIVITY/PRODUCT LAUNCHES

GSK Inks License With NanoBio to Market NB-001
CPN Establishes New Medical Nanobiotechnology R&D Center
IBM to Setup New Research Center in Wroclaw
Life Technologies and Zymera Ink Licensing Deal for Quantum Dots Technology
APR Acquires Nanotechnology Platform Technology for Preparing Biotechnology Products
Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research
Piedmont Triad to Institute Statewide Nanobiotech Center
Biocon and Abraxis Introduce ABRAXANE in India
Starpharma Launches a Research Reagent Kit
Monash Enters Into a Deal with National Fabrication Facility of Australia
Taiwan Inks Nanotechnology Collaboration Deal with Australia
Avanti Institutes New Targeted Drug Delivery Company, Chikujee Therapeutics
CytoViva Rolls Out New Research Tool for Nanotechnology
Dabur Obtains DCGI Approval for Nanoxel in New Indications
Researchers Discover New Nanoparticles for Treating Brain Infection
Capsulution Tests Nanoparticle-Based Drug Formulation for Improved Bio-Availability
Invitrogen Signs Agreement with Genisphere
Sigma-Aldrich Signs Deal With Nanoco Technologies
Unidym Sells First License Option for Patent Portfolio to MDA
Unidym Spins Off Carbon Nanotubes Therapeutics Business into Ensysce Biosciences
Nacalai USA and Nano-C Enter into Collaboration Agreement for HPLC Technology
Advanced Materials Technology Obtains License for LBL® Technology from Capsulution
Nanogen and The Elitech Group Announce Merger
NanoViricides Signs MCRADA Agreement with CDC for Rabies
Manhattan Scientifics Acquires Metallicum
HemCon Medical Technologies Acquires Alltracel Pharmaceuticals
CN Probes Inks Agreement With a Leading MEMS Foundry
PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym
Ondine Acquires Exclusive License from UCL Business
Dabur Introduces Nanotechnology Based Anti-Cancer Drug Delivery System – Nanoxel
Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes
Unidym Merges with Carbon Nanotechnologies

9.FOCUS ON SELECT GLOBAL PLAYERS

Aduro BioTech (USA)
Abraxis Bioscience, Inc (USA)
Arrowhead Research Corporation (USA)
Calando Pharmaceuticals, Inc. (USA)
Unidym, Inc. (USA)
Agilent Technologies Inc (USA)
Asklepios BioPharmaceutical Inc (USA)
Biosante Phosphate Pharmaceuticals, Inc. (USA)
Elan Pharmaceuticals (USA)
Flamel Technologies, Inc. (France)
Gilead Sciences Inc (USA)
Life Technologies Corporation (USA)
BioTrove, Inc. (USA)
Invitrogen Corporation (USA)
NanoBio Corporation (USA)
Nanogen, Inc. (US)
Nanophase Technologies Corporation (USA)
pSivida Ltd (Australia)
Sigma Aldrich Company (USA)
Starpharma Holdings Ltd. (Australia)
Dendritic Nanotechnologies, Inc. (USA)
SkyePharma Pharmaceuticals (UK)
Zyvex Instruments LLC (USA)

10.GLOBAL MARKET PERSPECTIVE

Table 13. World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 14. World Historic Review for Nanobiotechnology by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 15. World 13-Year Perspective for Nanobiotechnology by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Analytics by Product Segment

Table 16. World Recent Past, Current & Future Analysis for Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 17. World Historic Review for Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 18. World 13-Year Perspective for Nanomaterials by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 19. World Recent Past, Current & Future Analysis for Solid Inorganic Nanoparticles by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 20. World Historic Review for Solid Inorganic Nanoparticles by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 21. World 13-Year Perspective for Solid Inorganic Nanoparticles by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 22. World Recent Past, Current & Future Analysis for Nanocomposites by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 23. World Historic Review for Nanocomposites by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 24. World 13-Year Perspective for Nanocomposites by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 25. World Recent Past, Current & Future Analysis for Nanostructured Materials & Membranes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 26. World Historic Review for Nanostructured Materials & Membranes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 27. World 13-Year Perspective for Nanostructured Materials & Membranes by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 28. World Recent Past, Current & Future Analysis for Nanotubes and Fullerenes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 29. World Historic Review for Nanotubes and Fullerenes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 30. World 13-Year Perspective for Nanotubes and Fullerenes by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 31. World Recent Past, Current & Future Analysis for Other Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 32. World Historic Review for Other Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 33. World 13-Year Perspective for Other Nanomaterials by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Table 34. World Recent Past, Current & Future Analysis for Nanodevices/Tools by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 35. World Historic Review for Nanodevices/Tools by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart

Table 36. World 13-Year Perspective for Nanodevices/Tools by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

Analytics by Application

Table 37. World Recent Past, Current & Future Analysis for Nanobiotechnology by Application – Pharmaceuticals, Medical Devices, Medical Research and Others Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 38. World 9-Year Perspective for Nanobiotechnology by Application – Percentage Breakdown of Revenues for Pharmaceuticals, Medical Devices, Medical Research and Others for Years 2007, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

Outlook
Industry Overview
Public Sector Funding
Major Nanobiotechnology Institutions and Centers
The Nanobiotechnology Center (NBTC)
Key technological advances achieved by NBTC in recent years -
Principal NBTC Partners
Centre for Biologic Nanotechnology (CBN)
Centre for Biological and Environmental Nanotechnology (CBEN)
Regulatory Environment
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 39. US Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 40. US Historic Review for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 41. US 13-Year Perspective for Nanobiotechnology by Technology Segment –Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

2.JAPAN

A. MARKET ANALYSIS

Public Sector Funding
Strategic Corporate Development

B. MARKET ANALYTICS

Table 42. Japanese Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 43. Japanese Historic Review for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 44. Japanese 13-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

3.EUROPE

A. MARKET ANALYSIS

Outlook
Market Overview
European Union Banks Heavily on Nanobiotechnology
Nano2Life Network
Major Nanobiotechnology Networks in Europe As of the Year 2006
Public Sector Funding
Regulatory Environment
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks
Focus on Select Markets
Germany
France
United Kingdom
Russia
Russian Biotech Players Eye Partnerships with Indian Counterparts
Rest of Europe
Ireland
Market Overview
Key Research Institutions/Centers in Nanobiotechnology
The Tyndall National Institute
The Centre for Research on Adaptive Nanostructures and NanoDevices
The National Centre for Sensor Research
The Sami Nasr Institute for Advanced Materials Science
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 45. European Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 46. European Historic Review for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 47. European 13-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2003 2009 & 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Outlook
Public Sector Funding
Focus on Select Markets
Australia
Market Overview
Major Institutions
Commonwealth Scientific and Industrial Research Organisation (CSIRO)
India
Market Overview
Government Takes Big Initiatives to Promote Nanobiotechnology
Agriculture, Livestock Sectors to Warm Up to Nanobiotechnology Benefits
Korea
Taiwan
Nanotechnology in Medicine – Small Yet Growing Segment in Taiwan
Iran
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 48. Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 49. Rest of World Historic Review for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 50. Rest of World 13-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 140 (including Divisions/Subsidiaries - 147)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East